Search Results

You are looking at 1 - 10 of 41 items for :

  • "diabetic neuropathy" x
  • Refine by Access: All Content x
Clear All

expression of endothelial nitric oxide synthase in diabetic neuropathy, vascular disease and foot ulcer. Diabetes, 1998, 47 , 457–463. Primavera J. Endothelial dysfunction and the

Open access
Orvosi Hetilap
Authors:
Ferenc Sztanek
,
Ágnes Molnárné Molnár
, and
Zoltán Balogh

References 1 Kempler, P.: Clinical presentation and diagnosis of diabetic neuropathy. [A diabeteses neuropathia klinikai képe és diagnosztikája.] Orv

Restricted access
Orvosi Hetilap
Authors:
Ferenc Sztanek
,
Bernadett Balogh
,
Ágnes Molnár
,
Eszter Zöld
,
Nóra Tóth
,
András Áron Jakab
, and
György Paragh

–217. 5 Winkler G, Kempler P. Pathomechanism of diabetic neuropathy: background of the pathogenesis-oriented therapy. [A neuropathia diabetica patomechanizmusa: az oki kezelés elméleti háttere.] Orv

Open access

aging population, the prevalence of DM is increasing quickly all over the world ( 24 ). Diabetes-induced hyperglycemia results in macro- and microvascular complications, such as diabetic neuropathy (DN), nephropathy, and retinopathy ( 1 ). In both types

Restricted access

A diabeteses polyneuropathia okozta epidemiológiai és egészségbiztosítási betegségteher elemzése egészségbiztosítási adatok alapján

Assessing the epidemiological disease burden and health insurance treatment cost of diabetic polyneuropathy based on health insurance claims data

Orvosi Hetilap
Authors:
Tímea Csákvári
,
Diána Elmer
,
Noémi Németh
,
Zsuzsanna Kívés
,
István Wittmann
,
József Janszky
, and
Imre Boncz

.] Zafir Press, Budapest, 2012; pp. 199–222. [Hungarian] 6 Papanas N, Ziegler D. Risk factors and comorbidities in diabetic neuropathy: an update 2015

Open access

–644. A. Vlad et al. Therapeutic Approach to Diabetic Neuropathy; available at http://www.tmj.ro/dump_rezumathtml?id_numsar=1&id_articol=19 D. Ziegler , New Drugs to Prevent or Treat Diabetic Polyneuropathy

Restricted access
Hungarian Medical Journal
Authors:
Solomon O. Ugoya
,
Mayowa O. Owolabi
,
Tokunbo A. Ugoya
,
Fabian H. Puepet
,
Godwins O. Echejoh
, and
Adesola Ogunniyi

Background: Over three hundred million people worldwide were estimated to be become diabetic by year 2025. The rates of both obesity and malnutrition are on the increase worlwide. The goal of this study was to describe the relationship of body mass index (BMI) and diabetic peripheral neuropathy (DPN) in persons with diabetes mellitus. Research design and methods: A cross-sectional analysis of BMI and peripheral neuropathy was conducted among one hundred and twenty diabetic subjects, who were grouped based on presence or absence of DPN. Ninety of the diabetic persons had peripheral neuropathy, while thirty of the diabetic persons had no neuropathy. DPN was determined only by clinical assessment using an aspect of the Michigan Neuropathy Screening Instrument (MNSI). Result: The two groups were not different in BMI, total cholesterol and high density lipoproteins (HDL). The group without peripheral neuropathy had better glycaemic control; HB A1C = 5.9 ± 2.5 (%), shorter mean duration of diabetes = 5.3 ± 3.6 years and younger age. More of those with peripheral neuropathy were underweight (six compared to none ‘0’ of those without neuropathy). Similar result was obtained for morbid obesity ‘class 3’, although BMI had no significant effect on DPN after controlling for age, duration of DM and glycaemic control. Discussion and conclusion: Obesity is an index of insulin resistance which may account for poor glycaemic control and predispose to peripheral neuropathy and other complications. Weight loss depicts severity of type 1 DM which may account for complications. This pattern also depicts the trend in a sub-Saharan African city like ours with uneven distribution of wealth and resources hence the poor result in both the underweight and obese class 3.

Restricted access
Orvosi Hetilap
Authors:
Viktor Zoltán Szabó
,
György Lázár
,
Béla Borda
,
Csaba Lengyel
,
Tamás Várkonyi
,
Zoltán Hódi
, and
Bernadett Borda

painful diabetic neuropathy. Diabetes Care 2009; 32: 451–455. 2 Sun PC, Kuo CD, Chi LY, et al. Microcirculatory vasomotor changes are associated with severity of peripheral

Restricted access

A rheopheresiskezeléssel szerzett első hazai tapasztalatok

The first local experiences with rheopheresis treatment

Orvosi Hetilap
Authors:
Pál Soltész
,
Norbert Németh
,
Kristóf Gál
,
Melinda Vass
,
Ágnes Diószegi
,
Ferenc †Mechler
,
Klára Fekete
,
Viktória Somogyi
, and
László Módis

Összefoglaló. Háttér: A rheopheresis egy szelektív, extracorporalis, kettős kaszkádfiltrációs eljárás, mely előzetes plazmaszeparációt követően egy speciális filter segítségével kivonja a vérplazmából a hiperviszkozitásért felelős komponenseket, úgymint alacsony sűrűségű lipoprotein, lipoprotein(a), triglicerid, koleszterin, fibrinogén, α2-makroglobulin, Von Willebrand-faktor, immunglobulin-M. Módszer és Betegek: Klinikánkon az elmúlt 5 évben MONET filter alkalmazásával összesen 80 kezelést végeztünk hiperviszkozitással összefüggő, időskori száraz maculadegeneratióban, diabeteses alsó végtagi fekélyben, illetve neuropathiában. Eredmények: A dolgozatban beszámolunk kedvező klinikai tapasztalatainkról, a viszkozitás, a klinikai tünetek és az elektroneurográfiai paraméterek tükrében. Orv Hetil. 2021; 162(10): 375–382.

Summary. Background: Rheopheresis is a selective, extracorporeal, double cascade filtration method. After a previous plasma separation, with the help of a special filter it extracts compounds from blood plasma which are responsible for hyperviscosity such as low-density lipoprotein, lipoprotein(a), triglyceride, cholesterine, fibrinogen, α2-macroglobulin, Von Willebrand factor, immunoglobulin M. Method and Patients: In the past 5 years, with the application of MONET filter we performed 80 therapies to treat age-related macula degeneration, diabetic foot ulcers and neuropathy which are complicated with hyperviscosity. Results: The review describes our benefical clinical experiences in consideration of viscosity, clinical symptoms and electroneurography parameters. Orv Hetil. 2021; 162(10): 375–382.

Open access
Acta Physiologica Hungarica
Authors:
K. Tarhzaoui
,
A. Behar
,
R. Lestrade
,
C. Hort-Legrand
,
F. Cohen-Boulakia
, and
Paul Valensi

In rats with diabetes induced at weaning, pathological examinations have shown that the reduction of myelin thickness occurs earlier than axon size reduction. The aim of this study was to provide a detailed description of neurophysiological changes during nerve growth and maturation in rats with streptozotocin-induced diabetes in prepubertal stage. Five-day male Wistar rats received an injection of streptozotocin. Motor and sensory conduction velocities increased until 6.5 months in diabetic and control rats and at this age it became lower in diabetic rats. In diabetic rats, the amplitudes of the compound motor action potentials (CMAP) were lower by the 3 months and did not increase later. The amplitudes and areas of sensory action potentials (SNAP) increased until 9 months in both groups. SNAP duration decreased with ageing. Sensory peak 1 and peak 2 latencies became longer from 6.5 to 9 months in diabetic rats, with a longer latency difference between the 2 sensory peaks by 4 months. At 3 and 4 months of age, peak 1 and peak 2 latencies correlated with SNAP amplitude and duration in control rats but not in diabetic rats. In conclusion, in rats with early induced diabetes, the earliest electrophysiological impairments consist of lower CMAP amplitudes, and longer difference between latencies of sensory peaks 1 and 2. These sequential neurophysiological changes should be considered when testing new therapeutic approaches in diabetic neuropathy.

Restricted access